Should we really worry about "launch delays" of new drugs in OECD countries?

European Journal of Health Economics

Volumn 8, Issue 1, 2007, Pages 1-3

  Garattini, Livio ^a   Ghislandi, Simone ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; EDITORIAL; POLITICS; PRIORITY JOURNAL; PUBLICATION;

BIAS (EPIDEMIOLOGY); COST CONTROL; DEVELOPED COUNTRIES; DRUG APPROVAL; EUROPE; HUMANS;

EID: 33847093368     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-006-0022-5     Document Type: Editorial

References (12)

1. Vernon, J.A.: Examining the link between price regulation and pharmaceutical R&D investment. Health Econ. 14, 1-16 (2005)
2. Danzon, P.M., Wang, I.L., Wang, L.: The impact of price regulation on the launch delay of new drugs - evidence from twenty five major markets in the 1990s. Health Econ. 14, 269-295 (2005)
3. Lanjow, J.O.: Patents, price controls and access to new drugs: how policy affects global market entry. NBER working paper no. 11321 (May 2005)
4. Kyle, M.K.: Pharmaceutical price controls and entry strategies. Duke university working paper (2005)
5. Lichtenberg, F.: Do (more and better) drugs keep people out of hospitals? Am. Econ. Rev. 86, 384-388 (1996)
6. Lichtenberg, F.: The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001. Int. J. Health Care Financ. Econ. 5, 47-73 (2005)
7. Kessler, D.P.: The effects of pharmaceutical price controls on the cost and quality of medical care: a review of the empirical literature. US Department of Commerce and International Trade Administration (http://www.ita.doc.gov/td/ health/-)
8. Prescrire International: A review of new drugs and indications in 2002: financial speculation or better patient care? Prescrire Int. 12(64), 74-77 (2003)
9. Joppi, R., Bertelè, V., Garattini, S.: Disappointing biotech. BMJ 331, 895-897 (2005)
10. Apolone, G., Joppi, R., Bertelè, V., Garattini, S.: Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. Br. J. Cancer 93, 504-509 (2005)
11. Garattini, S., Garattini, L.: Drugs sales in four European countries still differ. BMJ 327, 1404-1405 (2003)
12. US Department of Commerce, International Trade Administration (December 2004) Pharmaceutical price controls in OECD countries